ReviewWorld journal of hepatology2015
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis.Drug design, development and therapy · 2017Pooled it
- Pooled it
- DNA methylation-driven genes in hepatocellular carcinoma patients: insights into immune infiltration and prognostic implications.Frontiers in medicine · 2025Article
- Immune regulation and therapeutic application of T regulatory cells in liver diseases.Frontiers in immunology · 2024Review
- Construction and validation of a necroptosis-related lncRNAs prognosis signature of hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Adjuvant therapy usingAnnals of hepato-biliary-pancreatic surgery · 2021Article
- Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.Cancers · 2021Review
- Adjuvant treatment strategy after curative resection for hepatocellular carcinoma.Frontiers of medicine · 2021Review
- Cytolytic Activity of Effector T-lymphocytes Against Hepatocellular Carcinoma is Improved by Dendritic Cells Pulsed with Pooled Tumor Antigens.Scientific reports · 2019Article
- Non-Cirrhotic Liver is Associated with Poor Prognosis of Hepatocellular Carcinoma: A Literature Review.Medical science monitor : international medical journal of experimental and clinical research · 2019Review
- HMQ-T-B10 induces human liver cell apoptosis by competitively targeting EphrinB2 and regulating its pathway.Journal of cellular and molecular medicine · 2018Article
- Immunomodulation in hepatocellular cancer.Journal of gastrointestinal oncology · 2018Review
- Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Molecular and cellular biochemistry · 2018Review
- Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo.Journal of cancer research and clinical oncology · 2017Article
- Phase I clinical study of personalized peptide vaccination combined with radiotherapy for advanced hepatocellular carcinoma.World journal of gastroenterology · 2017Article
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Immunotherapeutic approaches for hepatocellular carcinoma.Oncotarget · 2017Review
- Recent advances in hepatocellular carcinoma therapy.Pharmacology & therapeutics · 2017Review
- Brain metastases from hepatocellular carcinoma: recent advances and future avenues.Oncotarget · 2017Review
- Expression of CHODL in hepatocellular carcinoma affects invasion and migration of liver cancer cells.Oncology letters · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a common cancer worldwide with a poor prognosis. Few strategies have been proven efficient in HCC treatment, particularly for those patients not indicated for curative resection or transplantation. Immunotherapy has been developed for decades for cancer control and is attaining more attention as a result of encouraging outcomes of new strategies such as chimeric antigen receptor T cells and immune checkpoint blockade. Right at the front of the new era of immunotherapy, we review the immunotherapy in HCC treatment, from basic research to clinical trials, covering anything from immunomodulators, tumor vaccines and adoptive immunotherapy. The mechanisms, efficacy and safety as well as the approach particulars are unveiled to assist readers to gain a concise but extensive understanding of immunotherapy of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.